Conditions treated in China
What people come to China for, with treatments, hospitals, sourced prices and trial links.
CAR-T cell therapyChina's NMPA has approved at least eight CAR-T products since 2021, including satri-cel in June 2026, the first CAR-T approved for a solid tumor. Two...465 recruiting trials in ChinaMultiple myelomaThree BCMA-targeted CAR-T products are NMPA-approved in China for relapsed or refractory myeloma after at least three prior lines: equecabtagene (Fuca...166 recruiting trials in ChinaKnee arthroscopy and knee surgeryKnee arthroscopy and ligament surgery are routine at Chinese tertiary hospitals. National procurement in late 2023 cut sports medicine consumable pric...16 recruiting trials in ChinaLymphomaFor relapsed or refractory large B-cell lymphoma, China has four approved CD19 CAR-T products: axi-cel, relma-cel, ranicabtagene and inaticabtagene. O...585 recruiting trials in ChinaLeukemiaChina has approved inaticabtagene, a CD19 CAR-T, for adult relapsed or refractory B-cell ALL, and olverembatinib for resistant CML, including T315I-mu...399 recruiting trials in ChinaLung cancerChina has approved lung cancer drugs not yet FDA-approved, including ivonescimab (PD-1/VEGF; three NSCLC indications, US decision due November 2026) a...914 recruiting trials in ChinaLiver cancerChina approved camrelizumab plus rivoceranib (apatinib) as first-line treatment for unresectable liver cancer in January 2023; the FDA has issued thre...351 recruiting trials in ChinaEsophageal cancerChinese-developed PD-1 drugs are used for esophageal squamous cell carcinoma: camrelizumab is China-approved for it, and tislelizumab is FDA-approved...234 recruiting trials in ChinaBreast cancerChina approved trastuzumab rezetecan, a Hengrui HER2 antibody-drug conjugate, in March 2026 for HER2-positive advanced breast cancer after prior anti-...658 recruiting trials in ChinaNasopharyngeal cancerToripalimab, a Chinese PD-1 antibody approved in China for nasopharyngeal carcinoma, became the first FDA-approved NPC drug in October 2023. Chemoradi...151 recruiting trials in ChinaProton and heavy ion therapyMainland China had three operating heavy (carbon) ion centers by end 2024: Shanghai Proton and Heavy Ion Center, Wuwei and Lanzhou, plus proton center...45 recruiting trials in ChinaJoint replacement (hip and knee)Hip and knee replacement is widely performed in China. National volume-based procurement from 2022 cut average implant prices from about 35,000 to 7,0...15 recruiting trials in ChinaSpine surgerySpinal fusion, minimally invasive and endoscopic spine surgery are available at Chinese tertiary hospitals. The September 2022 national spine consumab...108 recruiting trials in ChinaCardiac surgery and interventionsCoronary stenting and open-heart surgery are routine at Chinese tertiary hospitals. National procurement from 2021 cut average coronary stent prices f...134 recruiting trials in ChinaNeurosurgeryBrain tumor, cerebrovascular and functional neurosurgery are offered at major centers such as Beijing Tiantan Hospital, which describes itself as Chin...69 recruiting trials in ChinaDental implantsUnder NHSA price governance from 2023, tertiary public hospitals cap the service fee for a routine single implant at about 4,500 yuan (some cities hig...4 recruiting trials in ChinaEye surgery (cataract, refractive, retinal)Cataract, refractive and retinal surgery are widely available at public eye hospitals and private chains. National procurement in November 2023 cut in...90 recruiting trials in ChinaHealth checkupsPublic tertiary hospitals and private clinics in major cities offer same-day multi-test checkup packages, often through international departments. Xin...Traditional Chinese medicine (TCM)TCM is regulated under the Traditional Chinese Medicine Law, effective July 1, 2017. Practitioners need a TCM physician qualification, and TCM clinics...65 recruiting trials in China